Skip to content

Total Equity at other companies

Sarepta Therapeutics, Inc. logo
Sarepta Therapeutics, Inc.SRPT
$1.51B+31.7%
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
$3.41B+34.4%
Insmed logo
InsmedINSM
$704.85M+611%
Dyne Therapeutics, Inc. logo
Dyne Therapeutics, Inc.DYN
$865.06M+29.3%
Taysha Gene Therapies, Inc. logo
Taysha Gene Therapies, Inc.TSHA
$211.94M+285%
Biogen logo
BiogenBIIB

Other financials

Income statement

See full
Revenue$2.0M-40.6%
Operating income-$57.3M-43.1%
Net income-$56.7M-44.4%
EPS (diluted)-$0.52+11.9%

Balance sheet

See full
Cash & equivalents$297.1M+41.1%
Total debt$20.7M-12.5%
Total assets$422.9M+23.0%

Cash flow

See full
Operating cash flow-$47.2M-48.3%
CapEx$165.0K+31.0%
Free cash flow-$47.4M-48.2%

Valuation

See full
Market cap$910.66M+145%
Enterprise value$634.23M+244%
P/S112.5×-10.3×

Profitability

See full
Operating margin-1,315.2%-4,060pp
Net margin-1,062.3%-251,151pp
FCF margin-1,247.7%-9,569pp

Returns & leverage

See full
Return on equity-57.4%+2.2pp
Debt / equity0.1×0.0×
Current ratio13.1×+2.2×

Where this comes from

Reported directly by Solid Biosciences Inc. in its filing.

Tagged under the XBRL concept us-gaap:StockholdersEquity.

The official record: Solid Biosciences Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Solid Biosciences Inc.'s total equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Solid Biosciences Inc.'s total equity?
Solid Biosciences Inc. (SLDB) reported total equity of $374.13M in Q1 2026.
How has Solid Biosciences Inc.'s total equity changed year-over-year?
Solid Biosciences Inc.'s total equity increased by 27.1% year-over-year, from $294.46M to $374.13M.
What is the long-term trend for Solid Biosciences Inc.'s total equity?
Over 5 years (2020 to 2025), Solid Biosciences Inc.'s total equity has grown at a 6.4% compound annual growth rate (CAGR), from $132.09M to $180.01M.
What does total equity mean?
Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.